New Data on CD40 Ligand Inhibitor for Relapsing MS : vimarsa

Novel agent led to sustained reduction of new lesions at 24 weeks

Related Keywords

Quebec , Canada , Gabrielle Macaron , Patrick Vermersch , Greg Laub , European Committee For Treatment , Americas Committee For Treatment , Research In Multiple Sclerosis , European Committee , Multiple Sclerosis , Americas Committee , Medpage Today , Senior Director ,